Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12050237 | 1.00 | AHCY (0.56) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL1908637 | 0.88 | AHCY (0.55) | AHCYADORA3ADORA1ADORA2A | |
| SCHEMBL26381988 | 0.86 | AHCY (0.57) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL293326 | 0.84 | AHCY (0.57) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL243600 | 0.84 | AHCY (0.57) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL293325 | 0.84 | AHCY (0.57) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL1841287 | 0.84 | AHCY (0.57) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL17243942 | 0.84 | AHCY (0.51) | AHCYADORA3ADORA1ADORA2A | |
| SCHEMBL4348432 | 0.82 | LMNA (0.48) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL3007619 | 0.80 | LMNA (0.46) | AHCYLMNATP53ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | ADORA2A, ADORA2B, ADORA1 | AHCY 2138/4885LMNA 2569/4885TP53 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.